The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) traces its origins to 1965, when NCI created an off-campus intramural program in the Division of Cancer Treatment at NCI and located it in the U.S. Public Health Service Hospital (USPHS) in Baltimore. After the USPHS hospitals were closed in 1974, the program was transferred to the University of Maryland. In 1982, the program was moved from a public to a private facility and renamed the University of Maryland Cancer Center, changing in 1996 to the UMGCC. The Center received its NCI designation in 2008.
The mission of the UMGCC is to conduct innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond. Clinical and research facilities are located on the UM medical campus in downtown Baltimore. The bridge that connects the clinical area of the hospital to the research laboratories in the UM School of Medicine Bressler Research Building illustrates the connection between the research scientists and clinicians giving patients care. The Center’s membership includes more than 270 faculty for research and patient care.
The comprehensive research programs at UMGCC include: Experimental Therapeutics, Hormone Responsive Cancers, Molecular and Structural Biology, Population Science, and Tumor Immunology and Immunotherapy. Research is conducted at the UM School of Medicine and in the Medical Center laboratories, with clinical research taking place through patient interactions within the Medical Center's inpatient and outpatient facilities.
The goal of the UMGCC’s interactive, multidisciplinary research program—consisting of both clinical and basic researchers—is to take advantage of discoveries in basic cancer biology and in the research programs in order to develop and apply innovative cancer treatment and prevention strategies. Researchers seek to describe the molecular mechanisms underlying specific clinical phenotypes and behaviors and apply these discoveries and strategies to the Maryland population and others, with a specific focus on cancer disparities.
The Center serves an inner city population with significant minority representation. In its emphasis on health disparities, UMGCC seeks to understand the basis for differences in cancer incidence, response, and survival in different populations. In addition to these studies of health disparities, another priority of the UMGCC is to increase the participation of underrepresented minorities in clinical trials, achieving a current participation rate of 30 percent.
The Center has comprehensive treatment programs for all types of cancer, each staffed by a multidisciplinary team of experts to care for the needs of each patient. There is a wide range of support services for patients, ranging from genetic and nutrition counseling to the Image Renewal Center. Both patients and their families are the focus of UMGCC’s education programs.
* This profile was provided by the University of Maryland Marlene and Stewart Greenebaum Cancer Center.